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We conducted genetic and functional analyses of 
isolates from a patient with group B streptococcal (GBS) 
necrotizing fasciitis and toxic shock syndrome. Tissue cul-
tures simultaneously showed colonies with high hemolysis 
(HH) and low hemolysis (LH). Conversely, the HH and LH 
variants exhibited low capsule (LC) and high capsule (HC) 
expression, respectively. Molecular analysis demonstrated 
that the 2 GBS variants were of the same clonal origin. Ge-
netic analysis found a 3-bp deletion in the covR gene of 
the HH/LC variant. Functionally, this isolate was associated 
with an increased growth rate in vitro and with higher inter-
leukin-8 induction. However, in whole blood, opsonophago-
cytic and intracellular killing assays, the LH/HC phenotype 
demonstrated higher resistance to host phagocytic killing. 
In a murine model, LH/HC resulted in higher levels of bac-
teremia and increased host mortality rates. These fi ndings 
demonstrate differences in GBS isolates of the same clonal 
origin but varying phenotypes.
Group B streptococci (GBS) are a major cause of sep-sis in neonates and pregnant women. The incidence of 
invasive GBS disease in nonpregnant adults is growing, in 
particular in elderly persons and in those with chronic un-
derlying conditions (e.g., diabetes mellitus) (1). Recently, 
cases of the severe, life-threatening syndromes of necrotiz-
ing fasciitis (1) and toxic shock syndrome due to GBS have 
been reported in neonates (2) and immunocompromised 
persons (3), reminiscent of a disease course more common-
ly associated with group A streptococci or Staphylococcus 
aureus. We report a case of GBS necrotizing fasciitis and 
toxic shock syndrome in a previously healthy person. We 
discovered 2 specifi c phenotypic variants of the bacterium 
from the tissue site of infection. Genetic and functional 
analysis of these variants provides insight into the potential 
contribution of specifi c bacterial virulence factors to these 
emerging GBS clinical syndromes.
Of GBS virulence factors, 2 of the best characterized 
are its exopolysaccharide capsule and the surface-associat-
ed toxin, β-hemolysin/cytolysin (β-h/c). The capsule con-
tributes to immune resistance by inhibiting complement 
deposition and activation on the bacterial surface, thereby 
reducing opsonophagocytic clearance (4). GBS production 
of β-h/c is encoded by the genes of the cyl operon (5,6) 
and is associated with direct lysis of a variety of eukaryotic 
cell types (7–9), infl ammatory activation (10–12), and viru-
lence in animal models (10,13,14). GBS β-h/c expression is 
linked to expression of an orange pigment with antioxidant 
properties (6,15), and these 2 factors act in concert to im-
pair macrophage-based immune clearance (16).
In the traditional clinical view of invasive GBS patho-
genesis, a bacterial isolate enters a normally sterile site from 
a focus of mucosal colonization or recent acquisition of the 
pathogen. However, as the present case will illustrate, se-
lective pressures in vivo may cause differential expression 
of certain GBS surface components during colonization or 
dissemination. Thus, in vivo pathogenesis from a bacterial 
perspective is likely more dynamic.
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Case Report 
A previously healthy 50-year-old man was admitted to 
the hospital with fever, severe pain and swelling of the right 
shoulder and arm, 1 week after moderate trauma. The ex-
tremity was erythematous, markedly swollen, and intensely 
tender. In the emergency department, the man’s condition 
rapidly deteriorated to septic shock. After receiving imme-
diate support with oxygen, intravenous fl uids, and antimi-
crobial agents (penicillin G, 3 g, 4×/day, and a single dose of 
120 mg gentamicin), he was transferred to the intensive care 
unit. In addition to mechanical ventilation and vasopressors, 
medical treatment included intravenous immunoglobulins 
and corticosteroids. Because necrotizing fasciitis was sus-
pected, wide debridement was performed, which confi rmed 
the clinical diagnosis. In tissue specimens obtained during 
the operation, gram-positive cocci with typical streptococ-
cal morphologic features were abundant. After samples un-
derwent overnight culture on blood agar plates and the or-
ganisms were identifi ed to species level, GBS was isolated. 
This pathogen also grew in cultures of blood obtained while 
the patient was in the emergency room. Antimicrobial drug 
treatment was changed to the combination of clindamycin 
and penicillin G. After a total of 3 repeated debridements 
and antimicrobial drug treatment for 6 weeks, the outcome 
was favorable. At follow-up after 6 months, the patient had 
only a slight radiating pain in the arm.
Methods
Sources of Bacteria
We included the following in specifi c, comparative as-
says: 2 serotype V GBS strains isolated from a colonized 
person (VK9) and a neonate with sepsis (CNCTC), GBS 
NEM316, and 1 group A streptococci serotype M1T1 iso-
late from a patient with streptococcal toxic shock syndrome 
(isolate 5448).
CAMP Test, Serotyping, Antimicrobial Susceptibility, 
and Pulsed-Field Gel Electrophoresis
Identifi cation of the isolates was confi rmed by CAMP 
testing, and serotype determination was achieved by using 
a coagglutination typing kit (Essum, Bacterium AB, Umeå, 
Sweden). Antimicrobial susceptibility and MICs were de-
termined by the Kirby-Bauer disk diffusion method and 
by Etest (AB Biodisk, Solna, Sweden), respectively. GBS 
isolates were subjected to pulsed-fi eld gel electrophoresis 
(PFGE) by using the restriction enzymes SmaI or XmaI 
(New England Biolabs, Ipswich, MA, USA) or ApaI (Pro-
mega, Madison, WI, USA), as described (17).
Measurement of Pigment and Hemolytic Activity 
Pigment was extracted as described (16). The optical 
density (OD) of the pigment extracts was measured at a di-
lution of 1:4 in a spectrophotometer (WPA Biowave, Bio-
chrom, Cambridge, UK). The hemolytic activity was deter-
mined by measuring hemoglobin release in the supernatant 
(by OD), after pigment extracts were incubated with an 
equal volume of 1% sheep erythrocytes for 1 h. Phosphate-
buffered saline (PBS), glucose alone, and erythrocytes 
lysed with 0.1% sodium dodecyl sulfate (SDS) were used 
as negative and positive controls, respectively. The results 
were related to SDS (100%) and expressed as hemolytic 
capacity. The hemolytic titer was assessed by a microtiter 
dilution method, as described previously (7).
Capsule Expression
Buoyance density of overnight bacterial cultures was 
determined by Percoll gradient centrifugation as described 
previously (18). To analyze surface sialic acid expression, 
strains were grown to mid log phase, washed, and resus-
pended in PBS to an OD of 0.4. Sialic acids were hydro-
lyzed with mild acid, then fi ltrated, neutralized, and deriva-
tized as previously described (19) for quantitative analysis 
by high-performance liquid chromatography. To visualize 
capsule expression, we incubated isolates on blood agar 
plates and in Todd-Hewitt broth (THB) overnight. Isolates 
were then washed and fi xed with Karnovsky solution. After 
polymerization, samples were sectioned with an ultrami-
crotome (Reichert-Jung Ultracut E, Leica, Wetzlar, Ger-
many), and analyzed by transmission electron microscopy 
(FEI, Philips, Morgani 268D, Aachen, Germany).
Genetic Analysis
PCR was used to amplify the cylA, cylE, covR, covS, 
rovS, and stk1 genes, as described previously (6), and se-
quences of amplicons were compared with the published 
genome of GBS serotype Ia strain A909 (20). Sequence 
alignment for all the genes showed >99% identity among 
GBS strains of different serotypes.
For heterologous expression of covR/S, the region was 
amplifi ed by PCR from the GBS genome by using the for-
ward primer 5′-GCGTCTAGAGAATAAGAAGGTTGG
TGTAGATGGG-3′ and reverse primer 5′-CGCGGATTC
GAAGCGCCTCTCTTATCACCTC-3′. The 2,286-bp am-
plicon was captured in pTTOPO according to the manu-
facturer’s instructions (Invitrogen, Carlsbad, CA, USA), 
then subcloned into expression vector pDCerm (21). The 
resulting pDC-CovRS plasmid was introduced into GBS 
by electroporation (22). Transformants were identifi ed by 
erythromycin resistance, and plasmid presence was con-
fi rmed by PCR.
RNA Isolation and Reverse Transcription–PCR 
Total bacterial RNA was extracted from overnight 
cultures of GBS by using an RNeasy Mini Kit (QIAGEN, 
Hilden, Germany) per manufacturer’s instructions, except 
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that bacteria were mechanically disrupted by using tubes with 
glass beads (Lysing Matrix B, MP Biomedicals, Solon, OH, 
USA). RNA samples were DNase treated (Turbo DNA-free; 
Ambion, Austin, TX, USA) to remove any contaminating 
DNA. One microgram of RNA was reverse transcribed to 
cDNA (Superscript First-Strand Synthesis Kit; Invitrogen) 
and used for PCR amplifi cation with the following primer 
sets: cfb forward 5′-CTGGAACTCTAGTGGCTGGTG-3′ 
and cfb reverse 5′-CCATTTGCTGGGCTTGATT-3′; cylK 
forward 5′-ATTTATCTGGCGATCGGTTG-3′ and cylK 
reverse 5′-CCTTTGGCAAACCAATTAAATAAC-3′; cylE 
forward 5′-GTCGTA GTGGACAGGCAATCAC-3′ and 
cylE reverse 5′-CGAAATGATCGACAATGCAG-3′; cpsG 
forward 5′-CATGAACAGCAGTTCAACCG-3′ and cpsG 
reverse 5′-CTGACATAAACGTCGCTGGAC-3′; and 
gyrA forward 5′-CTTGGTGATGGGACGTTCAGG-3′ 
and gyrA reverse 5′-GCTGAAGCAGCACGACGAAC-3′. 
PCR mixtures contained primers at a concentration 1 μM 
and PCR mix (Supermix; Invitrogen) in a volume of 15 
μL. Samples that had been prepared without reverse tran-
scriptase served as controls for DNA contamination. The 
PCR products were visualized by electrophoresis on a 1% 
agarose gel containing ethidium bromide.
Measurement of Growth Dynamics 
and Phenotype Stability
Bacterial growth rates were determined in THB and 
THB plus 1.5% yeast extract (THB + Y) by OD600 deter-
mination and enumeration of CFUs. Measurements were 
performed in triplicate. To evaluate phenotype stability, we 
passaged each variant isolate on blood agar (7 passages) 
and in various media (3 passages), including THB, THB 
+ Y, Granada, and chromogenic (Strepto B ID agar; bio-
Mérieux SA, Marcy-l’Etoile, France).
Cytokine Stimulation 
Peripheral blood mononuclear cells (PBMCs) were 
isolated from blood of 5 healthy donors by Ficoll-Hypaque 
gradient centrifugation (Lymphoprep; Axis Shield PoC AS, 
Oslo, Norway). PBMCs were stimulated with live bacteria 
(multiplicity of infection [MOI] ≈1:1) for 2 h. Uninfected 
PBMCs served as negative controls. Interleukin (IL)-1β, 
IL-8, and tumor necrosis factor α (TNF-α) in cell culture 
supernatants were determined by Luminex multiplex as-
says (BioSource International, Camarillo, CA, USA) and 
the Luminex100 instrument (Luminex, Austin, TX, USA).
Murine Model of GBS Infection 
Male CD-1 mice (Charles River Laboratories, San 
Diego CA, USA) 6–8 weeks of age were injected intrap-
eritoneally with 6–8 × 106 (low inoculum) or 5–7 × 107 
CFU (high inoculum) of either GBS phenotype variant and 
monitored for survival. After 6 h, blood was collected by 
retro-orbital puncture and assessed for levels of bacteremia 
by serial dilution plating on blood agar plates. Ethics ap-
proval for animal experimentation was obtained from the 
Animal Care Program of the University of California, San 
Diego, CA, USA.
Determinations of Bacterial Growth and Killing Rates 
in Human Whole Blood
Bacterial growth rates in freshly collected whole blood 
from 3 nonimmune human donors were determined by enu-
meration of CFUs. The blood was incubated with 10% vol-
ume of an overnight bacterial culture under mild agitation. 
Measurements were performed in duplicate.
For whole blood killing assays, inocula of 100 CFU 
in 100 μL were mixed with 300 μL human blood (n = 5 
donors) in heparinized tubes and incubated for 1–3 h with 
mild agitation. Dilutions were plated on blood agar for enu-
meration of CFU. Autologous plasma from nonimmune 
donors were used as controls.
Neutrophil Opsonophagocytic Killing Assays
Bacteria (CFUs ≈106) grown as described above were 
incubated with 10% normal human serum (i.e., source of 
complement) for 10 min and then mixed with autologous 
neutrophils (MOI ≈1:1) from the 5 nonimmune donors. 
Neutrophils were isolated by density gradient centrifuga-
tion using Polymorphprep solution (Axis Shield PoC AS). 
Controls included samples containing heat-inactivated se-
rum and neutrophils, serum without neutrophils, and PBS. 
Immediately before and after 60 min incubation, 100 μL 
of sample solutions were removed and plated on blood 
agar plates (23). To determine the kinetics of GBS survival 
within neutrophils, we pelleted and resuspended the cells 
in minimum essential medium supplemented with L-glu-
tamine, 125 μg/mL gentamicin (GIBCO, Invitrogen) and 
5 μg/mL penicillin G (24). After 30, 60, and 90 min, cells 
were lysed and CFU enumerated. Samples with only bac-
teria were used as a control for the bactericidal effects of 
antimicrobial drugs.
Statistical Analysis
Groups were compared by using a nonparametric 
paired test (Wilcoxon signed-rank test) and Kaplan-Meier 
plot; p values <0.05 were considered signifi cant. Statisti-
cal calculations were performed by using GraphPad Prism, 
Version 4.03 (Graph Software, San Diego, CA, USA).
Results
Pigment and Hemolytic Activity 
Culture of a tissue sample on blood agar plates dis-
played GBS colonies with 2 different phenotypes, either 
high hemolytic (HH) or low hemolytic (LH) (Figure 1, pan-
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el A). The difference in hemolysis was corroborated by 2 
different assays, which showed a 4- to 8-fold difference in 
hemolytic potential between the HH and LH variants (Fig-
ure 1, panel B). The HH phenotype had strong orange pig-
mentation; the pigmentation of the LH variant was diffi cult 
to detect in culture pellets or by spectrophotometric analy-
sis (Figure 1, panels C and D). In CAMP testing, however, 
the HH phenotype displayed a weaker reaction than the LH 
variant (Figure 1, panel E). The distinct phenotypes of the 
2 isolates proved to be stable after up to 7 passages in vari-
ous media.
Encapsulation
Evaluation of encapsulation by buoyant density cen-
trifugation showed high density for the HH variant (con-
sistent with low encapsulation [LC]) and low density for 
the LH strain (consistent with high encapsulation [HC]) 
(Figure 2, panel A). This difference in encapsulation was 
further confi rmed by direct quantifi cation of sialic acid lev-
els (Figure 2, panel B) and by imaging with transmission 
electron microscopy (Figure 2, panel C).
Clonal Origin of HH/LC and LH/HC Phenotypic Variants
Both phenotypes belonged to capsular serotype Ib 
and showed equivalent patterns of antimicrobial drug sus-
ceptibility or resistance. PFGE showed identical banding 
patterns after 3 restriction enzymes were used, which in-
dicates that the 2 phenotypes had the same clonal origin. 
To assess whether a genetic mutation could explain the 
observed phenotypic difference, we sequenced genes im-
plicated in β-h/c production or regulation. Although ampli-
fi cation and sequencing of cylE, cylA, covS, rovS, and stk1 
genes showed no difference between the isolates, a varia-
tion in the covR gene was observed. In the HH/LC vari-
ant, the covR sequence contained a 3-bp deletion, which 
eliminates a valine that was encoded at position 31 (LH/
HC = 20′-LELLHEGYDVVVETNGRE-37′ vs. HH/LC = 
20′-LELLHEGYDVV_ETNGRE-36′). The published se-
quence of the serotype Ia genome strain A909 is identical 
to that of the LH/HC variant.
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Figure 1. A) Hemolytic zone on blood agar plate after 48 h: Low hemolytic (LH) colony and high hemolytic (HH) colony. B) Hemolytic activity 
of the pigment extract presented as hemolytic capacity (left graph) relative to that of sodium dodecyl sulfate (100%) and as hemolytic 
titer (right graph) evaluated with a microdilution assay. Error bars indicate SEM. C) Phenotypic appearance of group B streptococci after 
overnight culture in Todd-Hewitt broth plus 1.5% yeast extract, displaying a white pellet (LH) and an orange pellet (HH). D) Absorbance 
profi le of the pigment extract. E) Results of CAMP testing, which display a stronger reaction with the LH than with the HH phenotype. 
Figure 2. A) Buoyant density analysis of the low hemolytic (LH) and 
high hemolytic (HH) strains, exhibiting lower and higher buoyant 
density, respectively. B) Quantifi cation of group B streptococci sialic 
acids expressed as fmol N-acetylneuraminic acid/1,000 CFUs of the 
LH and HH phenotypes. Error bars indicate SEM. C) Transmission 
electron microscopy of LH and HH phenotypic variants.
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Sequence Variation in covR and Phenotypic Variation
To confi rm that the covR 3-bp deletion contributed to 
the observed phenotypic changes in the HH/LC strain, we 
expressed the covR/S locus from the HH/LC variant on an 
expression plasmid in the LH/HC variant and GBS strain 
NEM316. Introduction of the mutated covR/S locus trans-
ferred the phenotypic appearance of the HH/LC variant to 
both the LH/HC and NEM316 strains, which resulted in 
increased hemolytic activity with increased pigmentation 
(Figure 3, panel A) and decreased reaction in the CAMP 
testing (Figure 3, panel B). In addition, encapsulation, mea-
sured by mean production of sialic acid, was reduced in 
the LH/HC expressing the HH covR/S locus by 29% com-
pared with the parent LH/HC strain (from 24 to 17 fmol 
N-acetylneuraminic acid/103 CFU). To validate that the 
observed phenotypic changes were the result of changed 
transcriptional regulation, reverse transcription–PCR was 
performed on RNA isolated from the wild-type and trans-
formant strains. The results demonstrated that introduction 
of the HH covR/S locus in either the LH/HC or NEM316 
background reduced expression of the cfb gene (encoding 
CAMP factor) and increased expression of the cyl genes 
(Figure 3, panel C).
Bacterial Growth Rate
In culture media the HH/LC phenotypic variant grew 
markedly faster than the LH/HC variant (Figure 4, panel 
A) and even outgrew the LH/HC isolate when both phe-
notypes were cultured together (Figure 4, panel B). Both 
phenotypes showed a faster growth rate than the 2 control 
isolates (samples from vaginal colonization and neonatal 
sepsis patients), with division times of 35 and 45 minutes, 
respectively (data not shown).
Cytokine Induction
We further investigated the potential of the 2 vari-
ants to induce proinfl ammatory responses in human cells. 
Stimulation of PBMCs from different donors showed that 
both GBS variants induced IL-1β and TNF-α, but no over-
all difference was noted between the 2 isolates. Because 
β-h/c has previously been shown to be a potent inducer of 
IL-8 and β-h/c expression increases 4-fold in parallel with 
growth rate (25), we expected that a difference in IL-8 re-
sponses would be greatest when live HH/LC and LH/HC 
strains were used as stimuli. Indeed, live HH/LC bacteria 
induced signifi cantly higher IL-8 levels than did the LH/
HC isolate (p = 0.03) (Figure 5).
Murine Toxic Shock Model
Virulence of the 2 isolates was tested in a murine toxic 
shock model, by injecting each mouse intraperitoneally 
with 5–7 × 107 CFU. Although all mice rapidly became 
bacteremic after inoculation, the bacterial load in blood 
was signifi cantly higher in mice infected with the LH/HC 
strain (p = 0.01) (Figure 6, panel A). Nevertheless, the HH/
LC bacteria caused death signifi cantly earlier (p = 0.0001) 
(Figure 6, panel B).
Resistance Toward Phagocytic Killing
The higher bacterial load of the LH/HC phenotype 
in the mice in comparison to the previously noted higher 
growth rate by the HH/LC phenotype in media (Figure 
4) suggested an increased resistance toward host immune 
defense in this phenotype. Indeed, in human whole blood, 
the LH/HC variant exhibited a higher growth rate than 
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Figure 3. A) Difference in pigmentation of the low hemolytic (LH)/
high encapsulation (HC) and NEM316 wild-type (WT) strains and 
their corresponding transformants expressing the covR/S locus 
of the high hemolytic (HH)/low encapsulation (LC) variant after 
overnight culture. B) CAMP testing with strains displayed according 
to panel A. The LH/HC variant and the NEM316 strain display a 
stronger reaction (arrows) than their corresponding transformants. 
C) Semiquantitative analysis of mRNA expression of CAMP factor 
(cftb), β-h/c (cylK and cylE) capsule (cpsG), and gyrA (housekeeping 
gene) using reverse transcription–PCR. Lane 1, LH/HC; lane 2, 
HH/LC; lane 3, LH/HC + pcovR HH; lane 4, NEM316 WT; lane 5, 
NEM316 + pcovR HH.
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HH/LC (data not shown). We therefore further assessed 
these fi ndings in several types of bactericidal assays. In 
a human whole-blood killing assay, the LH/HC pheno-
typic variant showed a higher survival index than the 
HH/LC variant at 2 different inocula (p = 0.03) (Figure 
7, panels A and B). A similar survival advantage for the 
LH/HC variant against whole-blood killing was also ob-
served in coculture assays in which both variants were 
used (data not shown). In an opsonophagocytic assay with 
purifi ed neutrophils and complement, the LH/HC isolate 
again demonstrated a higher survival index than the HH/
LC phenotype (p = 0.03) (Figure 7, panel C). The LH/
HC strain also demonstrated greater intracellular survival 
within neutrophils compared with the HH/LC variant (p = 
0.0012) (Figure 7, panel D).
We next sought to determine whether the enhanced 
resistance to bactericidal clearance would correspond to 
increased virulence in a low-dose infection model. Consis-
tent with the high-dose sepsis model, recovery of bacteria 
from the bloodstream at 6 h postinfection was signifi cantly 
higher in mice infected with LH/HC isolates than in those 
infected with the HH/LC phenotype (Figure 7, panel E). 
However, in contrast to high-dose challenge, in which 
death was accelerated in mice infected with the HH/LC 
variant, the increased resistance of the LH/HC against host 
phagocytic killing translated into sustained bacteremia and 
greater lethality (80% vs. 20%) in the lower dose infection 
model (Figure 7, panel F).
Discussion
The rate of invasive GBS in nonpregnant adults is in-
creasing, and most cases are found in elderly persons and 
those with underlying diseases (26). This study is based 
on a rare case of toxic shock syndrome and necrotizing 
fasciitis in an immunocompetent man without apparent 
risk factors. The GBS colonies obtained from the same 
tissue culture differed in phenotypic properties associated 
with 2 known GBS virulence factors, β-h/c cytotoxin and 
the exopolysaccharide capsule. A similar case was report-
ed by Sigge et al. (27); they described a case of neonatal 
sepsis caused by GBS in which hemolytic and nonhemo-
lytic colonies were displayed. Notably, only the hemo-
lytic strain could be isolated from the maternal vaginal 
tract. The observation of GBS isolates of the same clonal 
origin, but with varying phenotypes, as described in our 
study and that of Sigge et al. (27) supports the concept of 
differential expression of certain virulence factors, either 
during the process of colonization or during infection of 
specifi c anatomic sites. These phenotypic changes may 
occur in response to selective pressures exerted by the 
host immune response, providing the pathogen a survival 
benefi t. We therefore explored sequence differences in 
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Figure 4. Growth curve of group B streptococcal variants, i.e., low hemolytic (LH)/high encapsulation (HC) and high hemolytic (HH)/low 
encapsulation (LC), in Todd-Hewitt broth plus 1.5% yeast cultured in a separate tube (A) or together in the same tube (B). Graph presented 
as mean + SD. 
Figure 5. Interleukin (IL)– 8 induction in human peripheral blood 
mononuclear cells (PBMCs) (n = 5) using live bacteria. IL-8 
concentration measured in cell culture supernatants of PBMCs 
were after exposure to live high hemolytic (HH)/low encapsulation 
(LC) and low hemolytic (LH)/high encapsulation (HC) bacteria. 
Horizontal lines indicate the median.
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potential genetic clusters of this phenotypic variation and 
also investigated the functional differences between the 2 
phenotypes. We demonstrated that the 2 isolates have dis-
tinct phenotypic characteristics but are of the same clonal 
origin. Moreover, our fi ndings indicate that these varia-
tions in phenotypic appearance are associated with sig-
nifi cant differences in resistance to host phagocytic kill-
ing and in the clinical course of experimental infection. 
Finally, we provide indications that this phenotype switch 
may occur due to a mutation in an important regulatory 
gene (covR).
In our clinical pair of phenotypic variants, pigment 
production and hemolytic activity was reduced (but not 
eliminated) in 1 variant. However, no mutations in the cyl 
genes, the operon encoding genes required for β-h/c pro-
duction, were identifi ed. Sequence analysis of several regu-
latory genes showed that the HH/LC phenotype contained 
a 3-bp deletion in the covR gene. Previous studies have 
shown that complete deletion of the GBS covR/S may result 
in up-regulation of cyl genes involved in β-h/c expression 
(i.e., hemolytic activity), down-regulation of genes in the 
GBS cps operon for capsule expression, reduced survival 
in serum, and reduced virulence in animals (28,29). Ad-
ditionally, ΔcovR/S mutants show reduced CAMP activ-
ity, increased adherence to epithelial cells, and increased 
β-galactosidase activity (28); these changes illustrate the 
infl uence of covR/S on multiple genes involved in pheno-
typic, virulence, and biochemical properties of GBS.
To explore whether the 3-bp deletion in covR harbored 
by the HH/LC mutant may contribute to the observed 
phenotypic variation between the 2 clonal isolates, we ex-
pressed the covR/S locus from the HH/LC in the LH/HC 
variant, as well as the NEM316 GBS genome strain. In-
deed, overexpression of the covR/S HH locus in these 2 ge-
netic backgrounds resulted in a phenotype switch, i.e., in-
creased pigmentation associated with increased hemolytic 
activity, combined with decreased capsule production (as 
estimated by sialic acid quantitation) and CAMP reactivity. 
As demonstrated by reverse transcription–PCR, these ob-
served phenotypic changes were paralleled by the expected 
changes in the mRNA transcripts for genes encoding β-h/c 
(cylK, cylE), CAMP factor (cfb), and cpsG (an enzyme 
within the capsule biosynthetic operon).
Mutations in the related covR/S system of group A 
streptococci are induced under selective pressure of the in-
nate immune system and contribute to the pathogenesis of 
invasive infection caused by strains of the M1T1 serotype, 
which is associated with necrotizing fasciitis and toxic 
shock syndrome (30,31). Future detailed genetic, tran-
scriptional and mutational analysis of GBS invasive versus 
colonizing disease will be required to determine whether a 
similar paradigm exists in GBS.
Functional analyses of our clinical isolates showed 
that the HH/LC phenotype had a more rapid growth rate 
in culture media. Production of major GBS virulence fac-
tors (e.g., β-h/c, β-C protein) increases greatly with higher 
growth rate (25,32). In agreement with these results, the 
HH/LC phenotype induced a signifi cantly higher release of 
the proinfl ammatory chemokine IL-8 than did the LH/HC 
phenotype. Considering the strong association between IL-8 
serum levels and severity of sepsis (33,34), as well as the 
previously reported contribution of the β-h/c to the severe 
manifestations of septicemia in animal models (13,35–37), 
we compared the isolates in an in vivo sepsis model. Indeed, 
in a high-dose sepsis model in mice, the HH/LC phenotyp-
ic variant was associated with accelerated death, although 
blood CFU levels were lower than observed with the LH/
HC variant. We hypothesize that the accelerated death of 
mice infected with HH/LC isolates is a result of an over-
whelming infl ammatory response. The higher CFU levels 
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Figure 6. Murine toxic shock 
model (high inoculum). Groups 
of 5 mice were inoculated 
intraperitoneally with 5–7 × 
107 CFU of low hemolytic 
(LH)/high encapsulation (HC) 
or high hemolytic (HH)/low 
encapsulation (LC) group B 
streptococcal isolates per 
mouse. A) Level of bacteremia 
assessed after 6 h. Horizontal 
lines indicate the median. B) 
Kaplan-Meier survival plot. 
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of the LH/HC variant, on the other hand, may be associated 
with their increased resistance to phagocytic clearance, as 
comprehensively investigated in 4 different experimental 
models, i.e., whole blood, neutrophils and complement, in-
tracellular survival in neutrophils, and blood collection in 
the mouse model. Because complete elimination of β-h/c by 
targeted mutagenesis is known to diminish GBS resistance 
to phagocytic killing (16) and to reduce blood survival in a 
variety of animal models (10,12,14,16), the results imply a 
simultaneous up-regulation of a factor with a more critical 
role in phagocyte resistance in the LH variant. The hyper-
encapsulation in the LH variant is in line with this reason-
ing, because the capsule is known to impair opsonophago-
cytosis (4) and likely contributes to the enhanced resistance 
of the LH phenotype in vitro and in vivo.
In summary, our data show that phenotypic variants 
with markedly different expression of prominent virulence 
factors can arise in the course of invasive GBS infection 
in humans. These bacterial subpopulations may contribute 
to different aspects of disease pathogenesis. In the case re-
ported here, we could hypothesize that the HH/LC variant 
exerts toxin-mediated direct tissue injury and proinfl amma-
tory effects and that the LH/HC variant displays enhanced 
resistance to phagocytic clearance by virtue of increased 
capsule. The evolution of genetic switch mechanisms by 
the pathogen may allow it to conserve biochemical resourc-
es and synthesize the highest levels of capsule only under in 
vivo conditions of phagocyte selective pressure. The disad-
vantages of constitutive high-level capsule expression may 
lie in the known inhibitory effects of capsule on epithelial 
cell adherence (38) and the reduced growth rate of the LH/
HC variant as observed in our studies in optimal culture 
media. The potential for GBS phenotype variants should be 
a consideration in the diagnostic microbiology laboratory 
and in future analysis of GBS molecular pathogenesis. 
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